Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670576 | 1.00 | PYGB (0.44) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL2848040 | 1.00 | PYGB (0.44) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL29550937 | 0.87 | PYGB (0.49) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL1903565 | 0.87 | PYGB (0.41) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL20817264 | 0.87 | PYGB (0.41) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL23066316 | 0.87 | PYGB (0.41) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL20476841 | 0.86 | PYGB (0.51) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL3801496 | 0.86 | PYGB (0.51) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL2012475 | 0.86 | PYGB (0.51) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL28419458 | 0.86 | PYGB (0.51) | PYGBCA2CA9CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313163-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Ambrx, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024006542-A1 | ANTI-ROR1 ANTIBODIES AND ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-ROR1 ANTIBODIES OR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODIES AND ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023244517-A1 | INTERLEUKIN-2 PRODRUGS | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-4199968-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | Ambrx, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-4143233-A1 | METHODS OF PRODUCING FULL-LENGTH ANTIBODIES USING E.COLI | Sutro Biopharma, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4139340-A1 | HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER | Merck Sharp & Dohme LLC (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4117732-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Ambrx, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2022212899-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | AMBRX, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-3983410-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | Sutro Biopharma, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3980423-A1 | 5H-PYRROLO[3,2-D]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF | Sutro Biopharma, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-1951890-A4 | METHODS AND COMPOSITIONS COMPRISING NON-NATURAL AMINO ACIDS | AMBRX INC (US) | 2009-06-24 | — | — | EP | disclosed |
| EP-1974025-A4 | NON-NATURAL AMINO ACID POLYPEPTIDES HAVING MODULATED IMMUNOGENICITY | AMBRX INC (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1974025-A2 | NON-NATURAL AMINO ACID POLYPEPTIDES HAVING MODULATED IMMUNOGENICITY | Ambrx, Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1836314-A4 | MODIFIED HUMAN GROWTH HORMONE | AMBRX INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1951890-A2 | METHODS AND COMPOSITIONS COMPRISING NON-NATURAL AMINO ACIDS | Ambrx, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1836314-A2 | MODIFIED HUMAN GROWTH HORMONE | Ambrx, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007094916-A2 | NON-NATURAL AMINO ACID POLYPEPTIDES HAVING MODULATED IMMUNOGENICITY | AMBRX, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2006069220-A9 | MODIFIED HUMAN GROWTH HORMONE | AMBRX INC (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007059312-A2 | METHODS AND COMPOSITIONS COMPRISING NON-NATURAL AMINO ACIDS | AMBRX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2006069220-A2 | MODIFIED HUMAN GROWTH HORMONE | AMBRX, INC. (US) | 2006-06-29 | — | — | WO | disclosed |